secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001171843-22-003159
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass reports CTX-009 42% ORR in biliary tract cancers; to start U.S. Phase 2 in Q3 2022
--------------------------------------------------------------------------------

- CTX-009 + paclitaxel achieved 42% ORR (10 PRs) out of 24 patients with advanced biliary tract cancers.
- Clinical benefit rate 92% (22/24 patients had PR or stable disease); responses across all four BTC subtypes.
- Safety consistent with Phase 1: common AEs included hypertension (50%) and neutropenia (54.2%); manageable.
- Plans to initiate Stage 2 of Phase 2 study in the U.S. in Q3 2022, following Simon Two-Stage design criteria met.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184322003159/0001171843-22-003159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184322003159/f8k_050422.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-003159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer